Chemical Terrorism
A copy of the Chemical Terrorism Wall Chart is available as a multi-page file and as a one-page wall chart in Portable Document Format (PDF).
- Chemical agents act quickly. Rapid response is essential.
- Learn to recognize and diagnose the health effects of chemical agents.
- Chemical agents may contaminate you and your facility.
- Do not become a casualty! Implement procedures to decontaminate and treat incoming patients.
Awareness
Recognizing Chemical Terrorism-Related Illnesses
Adequate planning and regular training are key to preparedness for terrorism-related events. This wall chart is only a summary of important information. For more detail to assist you in preparedness planning, review the resources at the bottom of this wall chart.
Healthcare providers should be alert to illness patterns and reports of chemical exposure that might signal an act of terrorism. The following clinical, epidemiological and circumstantial clues may suggest a possible chemical terrorist event:
- Any unusual increase in the number of people seeking care, especially with respiratory, neurological, dermatological or gastrointestinal symptoms
- Any clustering of symptoms or unusual age distribution (e.g., chemical exposure in children)
- Any unusual clustering of patients in time or location (e.g., persons who attended the same public event)
- Location of release not consistent with a chemical's use
- Simultaneous impact to human, animal and plant populations
Any unusual symptoms, illnesses or clusters of these should be reported immediately. Notify the county health department and regional Poison Control Center.
Phone Numbers
Poison Control Centers | 1-800-222-1222 |
County Health Department | |
Consult phone book blue pages under "County Offices" | _____________ or www.nysacho.org |
New York State Department of Health (NYSDOH) | |
Bureau of Toxic Substance Assessment | 518-402-7800 |
Wadsworth Center Laboratories | 518-474-7161 |
After hours: NYSDOH Duty Officer | 1-866-881-2809 |
After hours: State Office of Emergency Management (SOEM) Watch Center | 518-292-2200 |
New York City Department of Health | |
Poison Control Center | 212-764-7667 |
Personal Protective Equipment (PPE)
DO NOT BECOME A CASUALTY!
Exposure can occur from inhalation of vapors, dermal contact or eye contact. The following general information can help responders/healthcare providers determine appropriate PPE.
Inhalation Exposure:
Protection from both vapors and particulates may be required when the chemical agent is being released. After release, protection from vapors is most important. Half-face and full-face respirators, with the appropriate canister, can provide protection from vapors. These operate by negative pressure and must be fit tested for optimal protection. Powered, air-purifying respirators (PAPR) and self-contained breathing apparatus (SCBA) provide even greater protection and operate under positive pressure so that fit characteristics are less important. Surgical and N-95 masks will not protect against inhalation of vapors.
Dermal Exposure:
Latex examination gloves provide very little protection from most chemical agents and can cause allergies. Gloves made of Viton, nitrile, butyl or neoprene provide better protection and, in some styles, allow adequate dexterity. However, the resistance of these materials to different chemicals varies and it is best to have a variety of gloves available. Double gloving may provide additional protection. Chemical-resistant aprons, suits and boots can also minimize dermal exposure.
Eye Exposure:
Full-face respirators, PAPR and SCBA will provide protection from both splashes and vapors. Protective eyewear, such as goggles or a face shield, will not provide protection from chemical vapors. Protective eyewear is necessary during decontamination to prevent splashing into eyes.
For more information, refer to OSHA Best Practices for Hospital-Based First Receivers of Victims from Mass Casualty Incidents Involving the Release of Hazardous Substances.
Decontamination Guidelines
Decontamination is the most important first step in patient care. Confirm or provide patient decontamination upon arrival.
To decontaminate:
- Immediately remove patient clothing. Removed clothing should be double bagged and sealed.
- Flush patient eyes with plenty of water or normal saline.
- Wash patient skin with soap and water. Do not abrade skin. Follow with a thorough water rinse.
- Do not use bleach, concentrated or diluted, on people.
Agents
Agent Type | Agent Names | Mode of Action | Any Unique Characteristics | Signs and Symptoms | Treatment | Other Patient Considerations |
---|---|---|---|---|---|---|
Nerve (See Table 2 below) |
|
|
|
|
|
|
Asphyxiant/ Blood (See Table 3 below) |
|
|
|
|
|
|
Choking/ Pulmonary- damaging |
|
|
|
|
|
|
Blistering/ Vesicant (See Table 4 below) |
|
|
|
|
|
|
Incapacitating/ Behavior- altering (See Table 5 below) |
|
|
|
|
|
|
Cytotoxic Protein |
|
|
|
|
|
|
*Frostbite may occur from skin contact with liquid arsine, cyanogen chloride or phosgene. |
Antidotes
Nerve agent antidotes may be obtained as auto-injector syringes. These devices rapidly deliver antidotes intramuscularly, typically to the thigh or buttocks. Atropine, in auto-injector form, is available as the AtroPen in amounts of 0.5, 1, or 2 mg. 2-PAM chloride, in auto-injector form, is available as the 600 mg ComboPen. A Mark I kit contains two auto-injector syringes; the smaller one with 2 mg atropine and the larger one with 600 mg 2-PAM chloride.
The spring-loaded design of the auto-injectors provides a forceful delivery that may cause tissue damage, especially to children and smaller patients. Children weighing less than 15 lb (about 7 kg), generally those younger than 6 months old, should not ordinarily be treated with the nerve agent antidote auto-injectors. In this age group, atropine should be individualized at doses of 0.05 mg/kg.
Patient | Mild/Moderate Effects1 | Severe Effects2 | Other Treatment |
---|---|---|---|
Child | Atropine: 0.05 mg/kg IM or IV (minimum 0.1 mg, maximum 5 mg); and 2-PAM chloride: |
Atropine: 0.1 mg/kg IM or IV (minimum 0.1 mg, maximum 5 mg); and 2-PAM chloride: |
Assisted ventilation after antidotes for severe exposure.
Repeat atropine at 2-5 minute intervals until Repeat 2-PAM chloride once at 30-60 minutes, then at one-hour intervals for 1-2 doses, as necessary. Diazepam for seizures: Other benzodiazepines (e.g. lorazepam, Phentolamine for 2-PAM chloride-induced |
Adult | Atropine: 2 to 4 mg IM or IV; and 2-PAM chloride3: |
Atropine: 6 mg IM; and 2-PAM chloride3: |
|
NOTE: 2-PAM chloride is pralidoxime chloride or Protopam Chloride. CHEMPACK: CHEMPACK is a federal program to provide nerve agent antidotes (Atropine, 2-PAM, Diazepam) to medical personnel during an emergency. Contact your county EMS coordinator, health department or emergency management office for more information. |
Table 3. Cyanide Antidote Recommendations
Victims whose clothing or skin are contaminated with hydrogen cyanide liquid or solution can secondarily contaminate response personnel by direct contact or through off-gassing vapors. Avoid dermal contact with cyanide-contaminated victims or with gastric contents of victims who may have ingested cyanide-containing materials. Victims exposed only to hydrogen cyanide gas do not pose contamination risks to rescuers. If the patient is a victim of recent smoke inhalation (may have high carboxyhemoglobin levels), administer only sodium thiosulfate.
Patient | Mild (conscious) | Severe (unconscious) | Other Treatment |
---|---|---|---|
Child | If patient is conscious and has no other signs or symptoms, antidotes may not be necessary. | Sodium nitrite1: 0.12 - 0.33 ml/kg, not to exceed 10 ml of 3% solution2 (300 mg) slow IV over absolutely no less than 5 minutes, or slower if hypotension develops and Sodium thiosulfate: |
For sodium nitrite-induced orthostatic hypotension, normal saline infusion and supine position are recommended.
If still apneic after antidote administration, consider sodium bicarbonate for severe acidosis. |
Adult | If patient is conscious and has no other signs or symptoms, antidotes may not be necessary. | Sodium nitrite1: 10 - 20 ml of 3% solution2 slow IV over absolutely no less than 5 minutes, or slower if hypotension develops and Sodium thiosulfate: |
|
|
Table 4. Lewisite Antidote Recommendations
British Anti-Lewisite (BAL, dimercaprol) was developed as an antidote for Lewisite and is used medicinally as a chelating agent for heavy metals. BAL can be toxic; healthcare providers should read the package insert carefully prior to use. Consult your regional Poison Control Center .
British Anti-Lewisite dosing | |||
---|---|---|---|
Indications | Dosing for systemic effects | Contraindications | Other Treatment |
Due to toxic side effects, BAL should be administered only to patients who have signs of shock or significant pulmonary injury.
There is evidence that BAL in oil, given intramuscularly, may reduce the systemic effects of Lewisite. BAL, administered IM, has no effect on local lesions of the skin, eyes or airways (See Other Treatment). |
IM: 3-5 mg/kg every 4 hours for 4 doses
IV: Never administer BAL in oil via IV route. |
Do not administer BAL if the patient presents with any of the following:
|
BAL skin and ophthalmic ointment decreases the severity of skin and eye lesions when applied immediately after decontamination; however, neither is currently manufactured. They can be used if available. |
Consult your regional Poison Control Center.
Physostigmine dosing | |||
---|---|---|---|
Test dose | Dosing information 1 | All routes | Contraindications |
If the diagnosis is in doubt, a dose of 1 mg might be given. If slight improvement occurs, routine dosing should begin. |
IM: 45 mcg/kg in adults (20 mcg/kg in children) or IV: 30 mcg/kg slowly (1 mg/min) or PO: 60 mcg/kg if patient is cooperative (dilute in juice due to bitter taste) |
Titrate every 60 minutes to mental status. | Do not administer physostigmine if the patient is experiencing any of the following:
|
|
Medical Preparedness References and Resources
- Agency for Toxic Substances and Disease Registry (ATSDR). 2001. Managing Hazardous Materials Incidents Vol. I, II, III. Division of Toxicology, U. S. Department of Health and Human Services. Public Health Service: Atlanta, GA. http://www.atsdr.cdc.gov/mhmi.html
- Centers for Disease Control and Prevention Public Health Emergency Preparedness and Response http://www.bt.cdc.gov/Agent/AgentlistChem.asp
- Chemical Casualty Care Division USAMRICD. 2000. Medical Management of Chemical Casualties Handbook, Third edition. U.S. Army Medical Research Institute of Chemical Defense (USAMRICD). Aberdeen Proving Ground: Aberdeen, MD. https://ccc.apgea.army.mil/sarea/products/handbooks/MMCC/mmccthirdeditionjul2000.pdf
- National Center for Disaster Preparedness. 2003. Pediatric Preparedness for Disasters and Terrorism: A National Consensus Conference, Executive Summary. Mailman School of Public Health, Columbia University: New York City.
- Textbook of Military Medicine - Medical Aspects of Chemical and Biological Warfare. https://ccc.apgea.army.mil/sarea/products/textbook/Web_Version/index_2.htm
- U.S. Army Edgewood Research, Development and Engineering Center. 1999. Technician EMS Course. Domestic Preparedness Training Program, Version 8.0. U.S. Army SBCCOM. Aberdeen Proving Ground: Aberdeen, MD.
Disclaimer
The information on this wall chart is meant to be a quick guide and is not intended to be comprehensive. Exercise professional judgment in determining antidote dosages. Also, consult the listed websites, references, and your regional Poison Control Center.
Updated: July 2005